Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1327-1331

  Lewis II, James S ^a,b,g   Lepak, Alex J ^c   Thompson III, George R ^b,e   Craig, William A ^c   Andes, David R ^c,d   Sabol Dzintars, Kathryn E ^b,f   Jorgensen, James H ^b,d  

^a UNIVERSITY HEALTH SYSTEM   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Avera McKennan Hospital and University Health Center   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZTREONAM; CLINDAMYCIN; COTRIMOXAZOLE; GATIFLOXACIN; GENTAMICIN; SULTAMICILLIN; VANCOMYCIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BETA HEMOLYTIC STREPTOCOCCUS; CELLULITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC FOOT; ERADICATION THERAPY; FEMALE; HUMAN; IN VIVO STUDY; MALE; MASTITIS; MEDICAL RECORD REVIEW; MIDDLE AGED; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; TREATMENT FAILURE; WOUND INFECTION; YOUNG ADULT;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; CLINDAMYCIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICE; MICE, INBRED ICR; MIDDLE AGED; RETROSPECTIVE STUDIES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; TREATMENT FAILURE;

EID: 84896807349     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01877-13     Document Type: Article

References (14)

1. Martin JM, Green M, Barbadora KA, Wald ER. 2002. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N. Engl. J. Med. 346:1200-1206. http://dx.doi.org/10.1056/NEJMoa013169. (Pubitemid 34984581)
2. York MK, Gibbs L, Perdreau-Remington F, Brooks GF. 1999. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J. Clin. Microbiol. 37:1727-1731. (Pubitemid 29235214)
3. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406. http://dx.doi.org/10.1086/497143. (Pubitemid 41581713)
4. CLSI. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. M100-S17. CLSI, Wayne, PA.
5. Lewis JS, II, Jorgensen JH. 2005. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin. Infect. Dis. 40:280-285. http://dx.doi.org/10.1086/426894. (Pubitemid 40110675)
6. Sutcliffe J, Tait-Kamradt A, Wondrack L. 1996. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob. Agents Chemother. 40:1817-1824. (Pubitemid 26277799)
7. LaPlante KL, Leonard SN, Andes DR, Craig WA, Rybak MJ. 2008. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim- sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob. Agents. Chemother. 52:2156-2162. http://dx.doi.org/10.1128/AAC. 01046-07. (Pubitemid 351758553)
8. Amezaga MR, McKenzie H. 2006. Molecular epidemiology of macrolide resistance in beta-haemolytic streptococci of Lancefield groups A, B, C and G and evidence for a new mef element in group G streptococci that carries allelic variants of mef and msr(D). J. Antimicrob. Chemother. 57: 443-449. http://dx.doi.org/10.1093/jac/dki490. (Pubitemid 43240196)
9. Desjardins M, Delgaty KL, Ramotar K, Seetaram C, Toye B. 2004. Prevalence and mechanisms of erythromycin resistance in group A and group B Streptococcus: implications for reporting susceptibility results. J. Clin. Microbiol. 42:5620-5623. http://dx.doi.org/10.1128/JCM.42.12.5620-5623.2004. (Pubitemid 40003766)
10. De Mouy D, Cavallo JD, Leclercq R, Fabre R. 2001. Antibiotic susceptibility and mechanisms of erythromycin resistance in clinical isolates of Streptococcus agalactiae: French multicenter study. Antimicrob. Agents Chemother. 45:2400 -2402. http://dx.doi.org/10.1128/AAC.45.8.2400-2402.2001.
11. Fitoussi F, Loukil C, Gros I, Clermont O, Mariani P, Bonacorse S, Le Thomas I, Deforche D, Bingen E. 2001. Mechanisms of macrolide resistance in clinical group B streptococci isolated in France. Antimicrob. Agents Chemother. 45:1889-1891. http://dx.doi.org/10.1128/AAC.45.6.1889-1891.2001. (Pubitemid 32466367)
12. Portillo A, Lantero M, Olarte I, Ruiz-Larrea F, Torres C. 2001. MLS resistance phenotypes and mechanisms in beta-haemolytic group B, C and G Streptococcus isolates in La Rioja, Spain. J. Antimicrob. Chemother. 47:115-116. http://dx.doi.org/10.1093/jac/47.1.115. (Pubitemid 32058767)
13. Leclercq R. 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 15:482-492. http://dx.doi.org/10.1086/324626. (Pubitemid 34112269)
14. Lepak AJ, Craig WA, Andes DR, Marchillo K, van Hecker J. 2012. Reduced activity of clindamycin against various streptococci with clindamycin-inducible resistance in the neutropenic thigh infection model, abstr D-1431. Abstr. 52nd Intersci Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.